Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.

Research square·2026

Same author

Duration of Initial Viremia Modulates Functional Properties of HIV-specific T Cell Receptors.

bioRxiv : the preprint server for biology·2026

Same author

CD8<sup>+</sup> T cell stemness precedes post-intervention control of HIV viraemia.

Nature·2025

Same author

CD8<sup>+</sup> T cell recall cytotoxicity during chronic treated HIV-1 infection is associated with limited reservoir size and activity.

medRxiv : the preprint server for health sciences·2025

Same author

Guidelines for T cell nomenclature.

Nature reviews. Immunology·2025

Same author

Bayesian estimation of HIV acquisition dates for prevention trials.

mBio·2025

Search research articles

Related Experiment Video

Updated: Dec 29, 2025

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Is an HIV vaccine possible?

M Juliana McElrath¹, Bruce D Walker

¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Journal of Acquired Immune Deficiency Syndromes (1999)

|July 10, 2012

Summary

Developing an effective HIV vaccine is crucial for a global solution. Durable protection requires robust immune responses, including B-cell and T-cell activation, to prevent infection or control disease.

Area of Science:

Immunology
Vaccinology
Infectious Diseases

Background:

Antiretroviral drugs show promise but are insufficient for a global HIV solution.
A successful HIV vaccine must provide durable protection against infection and disease progression.

Purpose of the Study:

To highlight the critical need for an effective HIV vaccine.
To discuss the immune responses required for vaccine-induced protection.
To address the challenges and resource constraints in HIV vaccine development.

Main Methods:

This study is a conceptual overview and does not involve specific experimental methods.
It synthesizes current understanding of immune correlates of protection against HIV.
It discusses the logistical and economic feasibility of global HIV prevention.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Related Experiment Videos

Last Updated: Dec 29, 2025

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Main Results:

An effective HIV vaccine is essential for a feasible global solution.
Protection likely requires Env-specific B-cell responses and CD4+ T-cell responses for antibody maturation.
HIV-specific CD8+ T-cell responses are important for controlling established infections.

Conclusions:

While an effective HIV vaccine is achievable, funding limitations and unknown correlates of protection pose significant challenges.
Innovative strategies are needed to maximize resources and advance HIV vaccine development.
A multi-pronged approach combining scientific and financial resource mobilization is essential.